SCHEMBL19743543

SCHEMBL19743543

Nc1cccc(-c2csc3ccnc(N)c23)c1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.55
AURKB Q96GD4 6/20 0.55
AURKA O14965 5/20 0.55
EPHB4 P54760 1/20 0.53
EIF2AK3 Q9NZJ5 1/20 0.48
ROCK2 O75116 5/20 0.47
MAP4K4 O95819 5/20 0.47
LCK P06239 5/20 0.47
FGFR1 P11362 5/20 0.47
FLT1 P17948 5/20 0.47
AXL P30530 5/20 0.47
FLT3 P36888 5/20 0.47
CSNK1A1 P48729 5/20 0.47
CSNK1D P48730 5/20 0.47
CSNK1G2 P78368 5/20 0.47
MAP4K2 Q12851 5/20 0.47
ROCK1 Q13464 5/20 0.47
CAMK2B Q13554 5/20 0.47
NTRK2 Q16620 5/20 0.47
TAOK1 Q7L7X3 5/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29503509 1.00 KDR (0.55) KDRAURKBAURKAEPHB4EIF2AK3
SCHEMBL29503496 1.00 KDR (0.55) KDRAURKBAURKAEPHB4EIF2AK3
SCHEMBL3529866 0.74 KDR (0.62) KDRAURKBAURKAEPHB4EIF2AK3
SCHEMBL3986247 0.74 KDR (0.48) KDRAURKBAURKAEPHB4ROCK2
SCHEMBL3525533 0.73 EPHB4 (0.74) KDRAURKBAURKAEPHB4EIF2AK3
SCHEMBL3979285 0.73 KDR (0.44) KDRAURKBAURKAEPHB4EIF2AK3
SCHEMBL3533248 0.72 KDR (0.68) KDRAURKBAURKAEPHB4ROCK2
SCHEMBL28803622 0.72 KDR (0.79) KDRAURKBAURKAEPHB4ROCK2
SCHEMBL28805994 0.72 KDR (0.59) KDRAURKBAURKAEPHB4ROCK2
SCHEMBL3531281 0.71 KDR (1.00) KDRAURKBAURKAEPHB4ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11833153-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-12-05 US disclosed
EP-3472165-B1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2023-09-06 EP disclosed
EP-3472165-B1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2023-09-06 EP disclosed
US-20230107393-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-04-06 US disclosed
US-11491158-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2022-11-08 US disclosed
CN-109311894-B N- (substituted-phenyl) -sulfonamide derivatives as kinase inhibitors 内尔维阿诺医学科学有限公司 2022-03-22 CN disclosed
US-20210128563-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2021-05-06 US disclosed
US-10918642-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2021-02-16 US disclosed
US-20200121686-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2020-04-23 US disclosed
US-10561660-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2020-02-18 US disclosed
US-20190201406-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2019-07-04 US disclosed
EP-3472165-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2019-04-24 EP disclosed
WO-2017220477-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230107393-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS ATF4, MAP3K1, MAP3K6 KDR 2509/4885AURKB 1157/4885AURKA 902/4885
US-20190201406-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS ATF4, MAP3K1, MAP3K6 KDR 2509/4885AURKB 1157/4885AURKA 902/4885
US-11491158-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors ATF4, MAP3K1, MAP3K6 KDR 2509/4885AURKB 1157/4885AURKA 902/4885
US-11833153-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors ATF4, MAP3K1, MAP3K6 KDR 2509/4885AURKB 1157/4885AURKA 902/4885
US-20210128563-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS ATF4, MAP3K1, MAP3K6 KDR 2509/4885AURKB 1157/4885AURKA 902/4885
US-10918642-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors ATF4, MAP3K1, MAP3K6 KDR 2509/4885AURKB 1157/4885AURKA 902/4885
US-20200121686-A1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS ATF4, MAP3K1, MAP3K6 KDR 2509/4885AURKB 1157/4885AURKA 902/4885
US-10561660-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors ATF4, MAP3K1, MAP3K6 KDR 2509/4885AURKB 1157/4885AURKA 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.